Diane Descamps researcher
Descamps, Diane, 19..-....
Descamps, Diane
VIAF ID: 193855419 (Personal)
Permalink: http://viaf.org/viaf/193855419
Preferred Forms
- 100 1 _ ‡a Descamps, Diane
- 100 1 _ ‡a Descamps, Diane, ‡d 19..-....
- 100 0 _ ‡a Diane Descamps ‡c researcher
4xx's: Alternate Name Forms (1)
Works
Title | Sources |
---|---|
Application de la génomique virale pour comprendre l'épidémiologie et l'évolution des virus à ARN dans le contexte d'épidémies passées et en cours. | |
Caractérisation du réservoir viral et des anticorps chez des enfants infectés par le VIH en suppression virologique au Mali. | |
Caractérisation moléculaire des réservoirs du VIH à différents stades cliniques de l'infection | |
Characterization of APOBEC3F/3G-induced defective viruses in HIV-2 infection. | |
Contribution of pharmacokinetic assessment in the selection of antiretroviral therapy (type and dose) in HIV-infected patients. | |
Control of chronic Epstein-Barr virus infection : consequences of altered B lymphocyte activation | |
DIVERSITE DES VIH : CONSEQUENCES SUR LA SENSIBILITE AUX ANTIRETROVIRAUX | |
Diversity of Human Immunodeficiency Virus 1 and evolution of its sensitivity to neutralizing antibodies : analyses at the individual and the populationnal levels. | |
Etude des codétections virales dans les prélèvements respiratoires : apport de la quantification virale normalisée pour la compréhension des infections respiratoires virales multiples. | |
Evaluation in vitro de la sensibilité du VIH-2 aux inhibiteurs de protéase | |
Evolution des profils de mutations associées à la résistance aux inhibiteurs de transcriptase inverse et de protéase chez des patients sous traitement antiretroviral comportant un inhibiteur de protease présentant un "microéchappement virologique" durable | |
gag genetic determinants associated with resistance to protease inhibitors in patients infected with HIV. | |
HIV status disclosure and risky sexual behavior among migrants from sub-Saharan Africa treated with antiretrovirals in France. | |
HIV type 2 tropism molecular determinants, implications in the pathophysiology of infection and therapeutic management. | |
Impact of integrase inhibitors on HIV reservoirs dynamics and compartmentalization. | |
Influence of GBV-C on the evolution of HIV-2 disease : application to the patients of HIV-2 national population. | |
Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109) | |
L'apport de l'évaluation pharmacocinétique dans le choix des antirétroviraux (nature et dose) chez la personne vivant avec le VIH | |
Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team). | |
Modeling the Time Course of CD4 T-Lymphocyte Counts According to the Level of Virologic Rebound in HIV-1–Infected Patients on Highly Active Antiretroviral Therapy | |
Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral load | |
Mutation V111I in HIV-2 reverse transcriptase increases the fitness of the nucleoside analogue-resistant K65R and Q151M viruses | |
National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011. | |
Natural evolution of CD4+ cell count in patients with CD4 >350 or >500 cells/mm3 at the time of diagnosis according to HIV-1 coreceptor tropism | |
Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors | |
New Highly Sensitive Real-Time PCR Assay for HIV-2 Group A and Group B DNA Quantification | |
New insights are game-changers in HIV-2 disease management | |
New insights in COVID-19-associated chilblains: a comparative study with chilblain lupus erythematosus | |
New Kaposi's sarcoma-associated herpesvirus variant in men who have sex with men associated with severe pathologies | |
A new mechanism of resistance of HIV-2 to integrase inhibitors: a 5 amino-acids insertion in the integrase C-terminal domain | |
New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations | |
NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens | |
No association between human herpesvirus or herpesvirus saimiri and idiopathic pulmonary fibrosis | |
No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir. | |
Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity | |
Performance evaluation of two SARS-CoV-2 IgG/IgM rapid tests (Covid-Presto and NG-Test) and one IgG automated immunoassay (Abbott) | |
Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients | |
Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant women | |
Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir | |
Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received | |
Predictive value of liver enzymes and inflammatory biomarkers for the severity of liver fibrosis stage in HIV/HCV co-infected patients | |
Presence of Human Papillomavirus (HPV) Apolipoprotein B Messenger RNA Editing, Catalytic Polypeptide-Like 3 (APOBEC)-Related Minority Variants in HPV-16 Genomes From Anal and Cervical Samples but Not in HPV-52 and HPV-58 | |
Presence of numerous stop codons in HIV-1 reverse transcriptase proviral DNA sequences from patients with virological response to HAART | |
Prevalence of hepatitis B among childbearing women and infant born to HBV-positive mothers in Togo | |
Prevalence of respiratory viruses among adults, by season, age, respiratory tract region and type of medical unit in Paris, France, from 2011 to 2016 | |
Primaquine as an innovative and targeted therapeutic strategy for HHV-8-associated diseases. | |
Quantification of proviral load of human immunodeficiency virus type 2 subtypes A and B using real-time PCR | |
R57K polymorphism in the human immunodeficiency virus type 1 protease as predictor of early virological failure in a cohort of antiretroviral-naive patients treated mostly with a nelfinavir-containing regimen | |
Removal of remdesivir's metabolite GS-441524 by hemodialysis in a double lung transplant recipient with COVID-19 | |
Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance | |
Reply to Das and Berkhout, "How Polypurine Tract Changes in the HIV-1 RNA Genome Can Cause Resistance against the Integrase Inhibitor Dolutegravir". | |
Reply to Yan and Muller, "Captisol and GS-704277, but not GS-441524, are credible mediators of remdesivir's nephrotoxicity" | |
Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes | |
Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients | |
Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network | |
Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial | |
Rôle des cellules dendritiques plasmacytoïdes dans la production d'IFN de type III et dans la présentation croisée du VIH | |
Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial). | |
Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen. | |
Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen | |
Serious neuropsychiatric adverse effects related to interaction between itraconazole and darunavir/ritonavir in an HIV-infected patient with cerebral histoplasmosis | |
Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients | |
Severe Reinfection With South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant 501Y.V2 | |
Short communication: Prevalence of HIV-1 transmitted drug resistance in Liberia | |
Specific diagnosis and follow-up of HIV-1 group O infection: RES-O data | |
Study of HIV-2 resistance mechanisms against protease inhibitors by using structural bioinformatic approaches. | |
Study of viral cοdetectiοns in respiratory specimens : nοrmalized viral loads quantitatiοn to understand multiple viral respiratory infectiοns.. | |
A survival method to estimate the time to occurrence of mutations: an application to thymidine analogue mutations in HIV-1-infected patients | |
Using viral genomics for the understanding of the epidemiology and evolution of RNA viruses in the context of past and ongoing outbreaks |